Skip to NavigationSkip to content

tuberculosis

GSK's tuberculosis vaccine shows efficacy over three years in HIV negative patients

Promising results have been revealed from a GlaxoSmithKline study, conducted in partnership with non-profit scientific research organisation IAVI, investigating the efficacy of the company’s M72/AS01E tuberculosis (TB) vaccine in HIV-negative adults with latent TB infection.

The study was conducted across 11 sites throughout Kenya, South Africa and Zambia – all TB-endemic regions – enrolling 3,573 HIV-negative participants between 18 and 50 years old.

FDA approve new drug for treatment-resistant TB

The US FDA has approved BPaL, the TB Alliance’s treatment for drug-resistant tuberculosis (TB).

The US regulator gave the go-ahead to the TB Allliance’s Pretomanid Tablets as part of a three drug combo, as a treatment for highly treatment-resistant TB of the lungs.

“The threat of antimicrobial-resistant infections is a key challenge we face as a public health agency,” said FDA Principal Deputy Commissioner, Dr Amy Abernethy.

New diagnostic tool predicts tuberculosis infection with 73% accuracy

A new diagnostic technology has demonstrated the ability to identify human tuberculosis (TB) infection and those at highest risk of developing the disease with high levels of accuracy.

PBD Biotech’s Actiphage assay is marketed as a test for detecting TB and Johne’s disease in cows via a blood or milk test, but has shown in clinical trials to also be very effective in human diagnosis.

FDA advisory panel backs TB Alliance's tuberculosis regimen

An FDA advisory panel has voted to recommend the investigational drug pretomanid, developed by the non-profit organisation TB Alliance, as a therapy for extensively drug-resistant tuberculosis and treatment-intolerant or non-responsive multidrug-resistant (MDR) tuberculosis, when combined with a regimen of bedaquiline and linezolid.

The US regulator’s Antimicrobial Drugs Advisory Committee voted 14-4 in favour of authorising the drug regimen for application in the US.

Global Fund seeks £11bn as progress slows in fight against malaria, TB and HIV

The Global Fund is seeking £11 billion worth of investment in an attempt to save 16 million lives in the fight against malaria, tuberculosis (TB) and HIV. The fund aims to cut the number of deaths from malaria, TB and HIV in half, by 2023.

J&J pledges to end global TB pandemic

Johnson and Johnson have announced that they are launching a 10-year initiative aimed at helping to end tuberculosis, the world’s most deadly infectious disease.

Through efforts to improve detection, broaden access to treatments, and accelerate R&D, the American pharma firm hope to save 1.8 million lives while preventing 12 million new TB infections, over the next ten years.

Eisai forms partnership to find new tuberculosis treatment

Eisai has teamed up with the Broad Institute, the Mycobacteria Research Laboratories at Colorado State University and the University of Chicago, entering into a new research partnership to develop a new treatment for tuberculosis (TB).

The new project comes as part of Eisai’s “human health care philosophy”, where the company says it is “proactively forming” partnerships with governments, international organisations and non-profits to accelerate development of more effective therapies for TB, malaria and neglected tropical diseases.

Body’s natural defence mechanism against TB discovered

TB bacterium

Research conducted by the Francis Crick Institute has revealed how the body protects itself from Mycobacterium tuberculosis, the bacterium responsible for TB, potentially opening up new avenues to combat the disease.

The natural method of combatting TB has been found to be at least partially dependent on immune cells known as macrophages. The immune cells surround the TB bacteria, before phagosomes are able to engulf and unleash enzymes to break down the bacterium.

Treatment combating multi-drug resistant TB posts positive results

Infectex, a Russian portfolio company of Maxwell Biotech Venture Fund, announced that it had found positive results from its latest Phase 2b-3 clinical trial of its drug for multidrug-resistant pulmonary tuberculosis. The compound was developed by US-based Sequella, a biotech focusing on developing novel treatments, and works by boosting existing therapies.

Bayer to collaborate on new treatments for tuberculosis with Universities of Dundee, Cape Town

The pharmaceuticals division at German-based Bayer will collaborate with the renowned medicinal chemistry and biology departments at the Universities of Dundee and Cape Town in an effort to develop vital new treatments for tuberculosis.

TB is the cause of one death every 23 seconds around the world, with 1.5 million dying each year from the disease with a further 9 million falling ill due to tuberculosis, mainly in developing countries. The three partners plan to improve on current first-line treatments that can take up to 6 months to cure patients.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches